Akatsuki Therapeutics

Akatsuki Therapeutics is a precision oncology company focused on the discovery and development of novel small molecule drugs targeting the DNA damage response (DDR) pathway. The company utilizes a proprietary discovery platform to identify synthetic lethal targets, aiming to exploit specific genetic weaknesses in cancer cells. Founded by Westlake Village BioPartners and led by experienced biotechnology executives, Akatsuki is advancing a pipeline of therapies designed to provide more effective and less toxic options for patients with difficult-to-treat malignancies. The firm is based in the biotechnology hub of South San Francisco, California.